OBJECTIVES: Obesity is an ever-growing problem in contemporary cardiac surgery. Although it accounts for many perioperative comorbidities, it has not been shown to increase mortality. Body mass index (BMI) is therefore not considered in the European System for Cardiac Operative Risk Evaluation (EuroSCORE). We sought to confirm whether this holds true for our own single-centre patient population. METHODS: Data from 15 314 consecutive patients receiving major cardiac surgery at our institution were analysed. Gender, age, BMI, EuroSCORE, urgency, redo status and all-cause in-hospital mortality were derived from our database. Mortality was grouped into 4 BMI categories. We created a logistic regression model to identify predictors of mortality. RESULTS: There were 11 034 males and 4280 females. Categorical mortality was 8.79% (underweight), 7.04% (normal weight), 5.16% (overweight), 6.30% (obese), rendering an inverse J-shaped pattern known as obesity paradox. Univariable regression detected significant predictors of mortality: rising age, female gender, urgent procedures, redo surgery (P < 0.001). BMI was no predictor (P = 0.575) but became significant with the multivariable analysis (P = 0.004). Its effect on mortality was exclusively indirect, being mediated through age (P < 0.001). Receiver-operating characteristics curve analysis also confirmed that BMI did not qualify as a risk factor. However, the overweight category was a predictor of lower mortality. CONCLUSIONS: Our findings from >15 000 patients confirm the obesity paradox showing the least mortality in the overweight group. They support the current EuroSCORE model in that BMI is no independent predictor of early mortality. However, such patients still carry the risk of comorbidities. Likewise, special care is required with underweight patients who show the highest in-hospital mortality.

OBJECTIVES: Liver cirrhosis increases the risk of death in patients having cardiac surgery, and the risk is markedly dependent on the actual stage. The EuroSCORE II, however, does not specifically address the risk of death of patients with liver cirrhosis. We investigated the predictive power of EuroSCORE II in patients with liver cirrhosis. METHODS: Between 2000 and 2020, a total of 218 patients with liver cirrhosis underwent cardiac surgery. To improve the predictive value of the EuroSCORE II, we calculated additional β-coefficients to include liver cirrhosis in the EuroSCORE IIb. The control group included 5,764 patients without liver cirrhosis from the same period. RESULTS: Of the 5,764 patients without cirrhosis, 8.9% died early. Of those with cirrhosis, 8.9% of 146 patients with Child A stage, 52.9% of 51 patients with Child B stage and 100% of 21 patients with Child C stage died. Moreover, the EuroSCORE II showed a poor predictive value for patients in Child B and C stages. The resulting values of calculated β using the area under the curve of the receiver operating characteristic and bootstrapping for Child stages as predictors of mortality were as follows: βA = 0.1640205, βB= 2.9911625 and βC= 6.2501248. By calculating the updated EuroSCORE IIb and regenerating the receiver operating characteristic curves, we were able to demonstrate an improvement in area under the curve values. Postoperative complications, need for extracorporeal membrane oxygenation or intra-aortic balloon pump implants, intensive care unit stays and hospital stays were significantly higher in cirrhotic patients with cirrhosis compared with patients without cirrhosis. The most common cause of liver cirrhosis was alcohol abuse (55.5%). CONCLUSIONS: Although patients with liver cirrhosis represent only a small proportion of cardiac surgical cases, the poor outcomes are particularly relevant in patients with advanced stages of the disease. Our study results show that Child class A patients show outcomes similar to those of patients without liver disease whereas Child class C patients appear to be nearly inoperable, i.e. can only be operated on with exceptional risks. Including these patients in the EuroSCORE II calculation would thus represent an improvement in preoperative mortality risk assessment.

Background and Objectives: Developing a prosthetic heart valve that combines the advantageous hemodynamic properties of its biological counterpart with the longevity of mechanical prostheses has been a major challenge for heart valve development. Anatomically inspired artificial polymeric heart valves have the potential to combine these beneficial properties, and innovations in 3D printing have given us the opportunity to rapidly test silicone prototypes of new designs to further the understanding of biophysical properties of artificial heart valves. TRISKELION is a promising prototype that we have developed, tested, and further improved in our institution. Materials and Methods: STL files of our prototypes were designed with FreeCad 0.19.2 and 3D printed with an Agilista 3200W (Keyence, Osaka, Japan) using silicones of Shore hardness 35 or 65. Depending on the valve type, the support structures were printed in AR-M2 plastics. The prototypes were then tested using a hemodynamic pulse duplicator (HKP 2.0) simulating an aortic valve cycle at 70 bpm with 70 mL stroke volume (cardiac output 4.9 L/min). Valve opening cycles were visualized with a high-speed camera (Phantom Miro C320). The resulting values led to further improvements of the prototype (TRISKELION) and were compared to a standard bioprosthesis (Edwards Perimount 23 mm) and a mechanical valve (Bileaflet valve, St. Jude Medical). Results: We improved the silicone prototype with currently used biological and mechanical valves measured in our setup as benchmarks. The regurgitation fractions were 22.26% ± 4.34% (TRISKELION) compared to 8.55% ± 0.22% (biological) and 13.23% ± 0.79% (mechanical). The mean systolic pressure gradient was 9.93 ± 3.22 mmHg (TRISKELION), 8.18 ± 0.65 mmHg (biological), and 10.15 ± 0.16 mmHg (mechanical). The cardiac output per minute was at 3.80 ± 0.21 L/min (TRISKELION), 4.46 ± 0.01 L/min (biological), and 4.21 ± 0.05 L/min (mechanical). Conclusions: The development of a heart valve with a central structure proves to be a promising concept. It offers another principle to address the problem of longevity in currently used heart valves. Using 3D printing to develop new prototypes provides a fast, effective, and accurate way to deepen understanding of its physical properties and requirements. This opens the door for translating and combining results into modern prototypes using highly biocompatible polymers, internal structures, and advanced valve layouts.

Background Conventional stented valves (CV) remain gold standard for aortic valve disease. Bovine prostheses have been improved and rapid deployment valves (RDV) have arrived in the recent decade. We compare clinical and hemodynamic short-term outcome of six bovine valves. Methods We retrospectively evaluated 829 consecutive patients (all-comers) receiving bovine aortic valve replacement (AVR). Four CV from different manufacturers (Mitroflow, Crown, Perimount, Trifecta) and two RDV (Perceval, Intuity) were compared in terms of pre-, intra-, and postprocedural data. A risk model for mortality was created. Results All valves reduced gradients. From 23 mm, all CV showed acceptable gradients. Twenty-one millimeter Mitroflow/Perceval and 19 mm Crown showed above-average gradients. As baseline data differed, we performed propensity matching between aggregated isolated CV and RDV groups. Cardiopulmonary bypass (CPB), clamp, and surgery times were shorter with RDV (87.4 ± 34.0 min vs 111.0 ± 34.2, 54.3 ± 21.1 vs 74.9 ± 20.4, 155.2 ± 42.9 vs 178.0 ± 46.8, p < 0.001). New pacemaker rate (10.1 vs 1.3%, p = 0.016) and the tendency toward neurologic events (8.9 vs 2.5%, p = 0.086) were higher using RDV, induced mainly by the Perceval. Early mortality was equal (2.5 vs 1.3%, p = 0.560). Revision for bleeding, dialysis, blood products, length-of-stay, gradients, and regurgitation was also equal. Risk analysis showed that low valve size, low ejection fraction, endocarditis, administration of red cells, and prolonged CPB time were predictors of elevated mortality. Conclusion Isolated bovine AVR has low mortality. Valves ≥ 23 mm show comparable gradients while the valve model matters < 23 mm. RDV should be used with care. Procedure-related times are shorter than those of CV but pacemaker implantation and neurologic events are more frequent (Perceval). Early mortality is low and valve performance comparable to CV.

Background: Cardiac tumors are rare, with a low incidence of between 0.0017 and 0.19%. The majority of cardiac tumors are benign and predominantly occur in females. The aim of our study was to examine how outcomes differ between men and women. Methods: From 2015 to 2022, 80 patients diagnosed with suspected myxoma were operated on. In all patients, preoperative, perioperative, and postoperative data were recorded. Such patients were identified and included in a retrospective analysis focused on gender-related differences. Results: Patients were predominantly female (n = 64; 80%). The mean age was 62.76 ± 13.42 years in female patients and 59.65 ± 15.84 years in male patients (p = 0.438). The body mass index (BMI) was comparable in both groups: between 27.36 ± 6.16 in male and 27.09 ± 5.75 (p = 0.945) in female patients. Logistic EuroSCORE (LogES) (female: 5.89 ± 4.6; male: 3.95 ± 3.06; p = 0.017) and EuroSCORE II (ES II) (female: 2.07 ± 2.1; male: 0.94 ± 0.45; p = 0.043), both scores to predict the mortality in cardiac surgery, were significantly higher in female patients. Two patients died early, within 30 days after surgery: one male and one female patient. Late mortality was defined as the 5-year survival rate, which was 94.8%, and 15-year survival rate, which was 85.3% in our cohort. Causes of death were not related to the primary tumor operation. The follow up showed that satisfaction with surgery and long-term outcome was high. Conclusion: Predominately female patients presented with left atrial tumors over a 17-year period. Relevant gender differences aside from that were not evident. Surgery could be performed with excellent early (within 30 days after surgery) and late results (follow up after discharge).